Phathom Corp (PHAT) - Market Capitalization

Phathom Pharmaceuticals (PHAT) growth relies on the sales expansion of innovative ulcer treatments in the US and support from insurance funds, with a financial reserve standing at 0.51. The company focuses on GERD therapy, utilizing advanced PCAB drugs for effective acid suppression. This chart demonstrates the price action of the asset, whose products outperform legacy analogs, enabling the company to maintain significant pricing power.

PHAT (Phathom Pharmaceuticals, Inc.) Market Value history from 07/04/2022 to 11/12/2026

Comprehensive metric breakdowns and analytics for Phathom (PHAT)

- current price and projected stock value:

Stock Price Phathom Pharmaceuticals, Inc.|PHAT - Fair Value Consensus

- market capitalization indicators:

Market Capitalization Phathom|PHAT - Enterprise Value

- issuer book value statistics:

Accounting Value per Share Phathom Pharmaceuticals|PHAT - Total Net Assets|Market Value to Book Value Ratio phathompharma.com|PHAT - Total Asset Value of Company

- issuer credit burden and liquidity indicators:

Total Debt to Capital Phathom Pharmaceuticals|PHAT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Phathom Pharmaceuticals|PHAT - Company Aggregate Debts|Debt to Book Capitalization Ratio Phathom|PHAT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Phathom Pharmaceuticals|Quick Ratio phathompharma.com

- net income and valuation multiples indicators:

PHAT - Net Profit|Future Profit Phathom Pharmaceuticals|PHAT - Company Value to Net Income|Forward P/E Multiple Phathom Corp|PHAT - Price to Net Income Growth Ratio|EV/EBITDA Multiple Phathom|PHAT - Operating income before deduction of amortization|Net earnings per share for the last 12 months Phathom Pharmaceuticals|PHAT - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months phathompharma.com|PHAT - Earnings per share trend in current year|Earnings growth forecast for next year Phathom Pharmaceuticals

Fundamental company analysis:PHAT (Phathom Pharmaceuticals, Inc.)

A conservative investor assesses the fundamental value of an asset through the aggregate market value of all issued shares, which allows for the rapid identification of business overvaluation or undervaluation. By analyzing the company's market capitalization on the exchange, one can see how the stability of the US domestic market and the absence of geopolitical risks in gastroenterology support the value of Phathom Pharmaceuticals (PHAT), minimizing the probability of a sudden price collapse.

Key competitors